B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Tough-to-Treat blood cancers
Disease control Recruiting nowThis trial investigates CRC01, a therapy made from a patient's own immune cells that are genetically modified to recognize and attack cancer cells. It is for adults with large B-cell lymphoma or B-cell acute lymphoblastic leukemia that has returned or not responded to previous tr…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Curocell Inc. • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
Combination therapy aims to keep leukemia in check after transplant
Disease control Recruiting nowThis study tests whether adding the drug blinatumomab along with a low dose of donor immune cells (called donor lymphocyte infusion) can help prevent relapse in people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who have already had a stem cell transplant. The trea…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
New Dual-Target CAR T-Cell therapy aims to beat relapsed childhood cancers
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
CAR t cells aim to lock in remission for leukemia patients
Disease control Recruiting nowThis study tests a CAR T-cell therapy called obe-cel in adults with B-cell acute lymphoblastic leukemia (ALL) whose cancer is in complete remission with no detectable cancer cells. The goal is to see if obe-cel can prevent the cancer from coming back. About 40 participants will r…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Supercharged cord blood cells take on resistant blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immune cell therapy for people with several kinds of blood cancers that have come back or stopped responding to treatment. The therapy uses natural killer (NK) cells from donated cord blood, which are genetically modified to better recog…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New CAR-T therapy aims to keep High-Risk leukemia in remission
Disease control Recruiting nowThis study tests a new type of immunotherapy called CD22/CD19 dual-target CAR-T cells in people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who have already achieved their first remission after standard treatment. The goal is to see if this therapy can safely and e…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells take on tough leukemias
Disease control Recruiting nowThis trial tests a therapy where a person's own immune cells are modified to attack cancer cells carrying a protein called CD19. It is for adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or B-cell acute lymphoblastic leukemia that has not responded to standa…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells take aim at leukemia that evades standard therapy
Disease control Recruiting nowThis trial investigates a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia (B-ALL) whose cancer has stopped responding to anti-CD19 treatment. The therapy uses a patient's own immune cells, modified to target several other markers on leukemia cel…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to wipe out leukemia cells for good
Disease control Recruiting nowThis early-stage trial tests a combination therapy for B-cell acute lymphoblastic leukemia (B-ALL). It uses specially engineered immune cells (CAR-T cells and CTLs) followed by a dendritic cell vaccine to target multiple cancer markers. The goal is to achieve a very deep remissio…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Second-Chance CAR-T: could Off-Spec cells still fight cancer?
Disease control Recruiting nowThis phase 3 trial is testing a CAR-T cell therapy called tisagenlecleucel that didn't quite meet commercial release standards. It's for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma who have no other approved options. The study will check if th…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New CAR-T therapy aims to keep leukemia in remission
Disease control Recruiting nowThis study tests a new immune cell therapy (dual-target CD22/CD19 CAR-T cells) as a consolidation treatment for people with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) who are in remission. The goal is to see if it is safe and can help prevent the cancer from coming…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Personalized chemo boosts CAR T-Cell success in young leukemia patients
Disease control Recruiting nowThis study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug trial hopes to shrink tumors in kids with Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a drug called zilovertamab vedotin in children and young adults whose blood cancers (like certain leukemias and lymphomas) or solid tumors (neuroblastoma, Ewing sarcoma) have come back or not responded to treatment. The goal is to see if the drug is safe and can …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for tough leukemia: MK-1045 takes on standard therapy
Disease control Recruiting nowThis study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo therapy aims to beat leukemia in young adults
Disease control Recruiting nowThis phase III trial is testing whether adding inotuzumab ozogamicin—a drug that targets cancer cells—to standard chemotherapy can improve outcomes for young adults (ages 18-39) newly diagnosed with B-cell acute lymphoblastic leukemia. About 310 participants will be enrolled. The…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for kids with hard-to-treat leukemia: combo therapy trial opens
Disease control Recruiting nowThis study tests a combination of chemotherapy drugs (mini-Hyper-CVD) plus three targeted drugs (rituximab, inotuzumab ozogamicin, and blinatumomab) in children and young adults whose B-cell acute lymphocytic leukemia has come back or not responded to treatment. The goal is to se…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Engineered immune cells take aim at childhood leukemia in new trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called CD123-CAR T cells for children and young adults (up to age 21) with certain types of leukemia or related blood cancers that have come back or not responded to standard therapy. The treatment involves collecting the patient's own…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New Dual-Target CAR-T therapy takes on tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called DuoCAR20.19.22-D95 for adults with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in the lab to better recognize and attack…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New CAR-T study aims to boost cancer treatment success
Disease control Recruiting nowThis study looks at how well CAR-T cell therapy works for people with certain blood cancers like lymphoma and leukemia. Researchers will track how the modified immune cells grow and last in the body after infusion. The goal is to see if this treatment is effective in real-world s…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New immune cell therapy targets Hard-to-Treat leukemia in early trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called CD19 t-hANK for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back after previous treatments. The therapy uses specially designed immune cells to attack cancer cells. Up to 10 participant…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Can a simple timing change make leukemia therapy safer?
Disease control Recruiting nowThis study tests whether giving a chemotherapy drug (methotrexate) into the spinal fluid before and during blinatumomab treatment can prevent nerve-related side effects in adults with acute lymphoblastic leukemia. The trial enrolls 20 people receiving their first cycle of blinatu…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New CAR-T therapy aims to save kids with Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy, called UCD19 CAR-T, in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) or B-cell non-Hodgkin lymphoma (B-NHL) that has come back or not responded to standard treatment. The therapy is made locally to sp…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Experimental CAR-T therapy targets tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called CLIC-2201 for people with B-cell cancers (like certain leukemias and lymphomas) that have come back or not responded to standard care. The treatment involves collecting a patient's own immune cells, modifying them to target a pr…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New CAR T-Cell therapy aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis phase 2 trial tests KTE-X19 (Tecartus), a personalized CAR T-cell therapy, in adults with B-cell acute lymphoblastic leukemia who are in remission but still have tiny amounts of cancer cells (minimal residual disease). The goal is to see if this treatment can clear those lef…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Gene therapy injection takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Double-Barreled CAR t attack shows promise for tough childhood leukemia
Disease control Recruiting nowThis study tests a new approach for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. It combines two types of engineered immune cells (CAR T cells) that target different markers on cancer cells (CD19 and …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Hospital-Made cancer fighters: new CAR-T trial for leukemia
Disease control Recruiting nowThis study is testing whether a personalized cell therapy called MB-CART19.1 can be manufactured right at the hospital for children and adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. The therapy uses the patient's own i…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: King Hussein Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New immunotherapy combo aims to treat leukemia without chemo
Disease control Recruiting nowThis study tests a sequence of two immunotherapy drugs, blinatumomab and inotuzumab ozogamicin, in people with B-cell acute lymphoblastic leukemia (B-ALL). It includes newly diagnosed patients who are older or too frail for intensive chemotherapy, as well as those whose cancer ha…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New stem cell transplant method shows promise for kids with tough blood cancers
Disease control Recruiting nowThis study tests a new way to do stem cell transplants for children with blood cancers like leukemia. It uses a half-matched family donor and removes certain immune cells from the donated cells to lower risks. The goal is to see if this method is safe and helps the child's body a…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New CAR t therapy targets hidden leukemia cells in adults
Disease control Recruiting nowThis early-stage trial tests a new type of immunotherapy (CAR T cells) in adults with B-cell acute lymphoblastic leukemia (B-ALL) who still have tiny amounts of cancer cells after their first round of treatment. The goal is to see if the therapy is safe and can eliminate these le…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New CAR t-cell combo aims to beat leukemia relapse
Disease control Recruiting nowThis study tests two approaches for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. One group gets a sequence of two types of CAR T-cells (targeting CD19 and CD22), while the other gets one type of CAR T-cell followed by a stem ce…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Donor immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-phase trial tests a two-step approach for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. First, patients receive donor-derived CD19 CAR T cells, then a stem cell transplant from the same donor, followed by donor-derive…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take on childhood leukemia in new trial
Disease control Recruiting nowThis phase 2 trial is testing a personalized cell therapy called CART19 in children and young adults with certain high-risk forms of B-cell acute lymphoblastic leukemia (B-ALL). The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack c…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for tough leukemia: capivasertib combo enters human trials
Disease control Recruiting nowThis study tests whether adding the experimental drug capivasertib to a standard treatment (venetoclax plus low-intensity chemotherapy) is safe and effective for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma that has come back or not responded to prior …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New CAR-T therapy SYNCAR-100 enters early human testing for tough leukemia
Disease control Recruiting nowThis early-phase study tests SYNCAR-100, a type of cell therapy (CAR-T), in 16 adults with CD19-positive B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. Participants receive four weekly injections, then are followed for safety and tu…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Can immune booster cells revive failing CAR-T therapy in leukemia?
Disease control Recruiting nowThis study tests whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 213 participants will be randomly assigned to receive eith…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug cocktail IoVeX offers hope for relapsed leukemia patients
Disease control Recruiting nowThis early-phase trial tests whether a combination of three drugs—inotuzumab ozogamicin, venetoclax, and dexamethasone (IoVeX)—is safe for children and adults with relapsed B-cell acute lymphoblastic leukemia (B-ALL). About 28 participants will receive the drugs over one or two 2…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo therapy aims to boost CAR t-cell success in hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests a radioactive drug (131-I apamistamab) given before CAR T-cell therapy for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. The goal is to find a safe dose and see if the combination is tolera…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Double CAR t attack: new trial targets leukemia that escapes first therapy
Disease control Recruiting nowThis early-phase trial tests whether giving a second type of CAR T cell therapy (targeting CD22) after the standard CD19 CAR T therapy is safe and feasible for children and young adults with relapsed or hard-to-treat B-cell leukemia. About 20 participants will receive the standar…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug YK012 tested in early leukemia trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called YK012 in 46 people with B-cell acute lymphoblastic leukemia (B-ALL). The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of fighting the cancer. Participants will receive YK012 throu…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for kids with tough leukemia: antibody drug tafasitamab enters trial
Disease control Recruiting nowThis study tests a drug called tafasitamab in children aged 3 to 17 with B-cell leukemia that has come back or not responded to treatment. The drug is an antibody that helps the immune system find and kill leukemia cells. The trial has two parts: first, finding the best dose, and…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Off-the-Shelf CAR t cells take on tough lymphomas and leukemias
Disease control Recruiting nowThis early-phase trial is testing a new type of CAR T cell therapy called Azer-cel, which is made from healthy donor cells rather than the patient's own cells. It aims to treat adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and relat…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take on childhood blood cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new type of immune therapy called CD70-CAR T cells in children and young adults up to age 21 with blood cancers that have come back or not responded to treatment. The therapy involves taking the patient's own immune cells, engineering them to recogn…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New mRNA CAR-T therapy aims to tackle tough blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that uses mRNA to target two proteins (CD19 and CD20) on cancer cells. It is for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The goal is to see if it is safe and effective, with up to …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Fresh donor cells take on childhood leukemia in early trial
Disease control Recruiting nowThis early-stage trial is testing a one-time infusion of specially engineered immune cells from a healthy donor in 24 children and young adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The main goal is to check safety and find the…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New Dual-Target CAR t therapy offers hope for kids with tough leukemia
Disease control Recruiting nowThis study tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) on leukemia cells. It is for children whose B-cell acute lymphoblastic leukemia has come back or not responded to standard treatments. The main goal is to find a safe dose and see if the t…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for leukemia patients: drug targets hidden cancer cells after transplant
Disease control Recruiting nowThis phase 2 trial tests the drug inotuzumab ozogamicin in 42 adults with B-cell acute lymphoblastic leukemia who have minimal residual disease (MRD) after a stem cell transplant. MRD means a few cancer cells remain undetectable by standard tests but can cause relapse. The drug a…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Sheng-Li Xue, MD • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New 'Sandwich' strategy aims to cut leukemia relapse without donor transplant risks
Disease control Recruiting nowThis early-phase trial tests a two-step treatment for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot have a standard donor stem cell transplant. First, patients receive the drug blinatumomab to clear any remaining cancer cells, then they undergo their own stem…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Engineered immune cells take aim at childhood leukemia
Disease control Recruiting nowThis Phase 1 trial is testing a new type of immunotherapy for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not gone away. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack leukem…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug cocktail aims to tackle tough leukemias
Disease control Recruiting nowThis early-phase trial is testing a new drug called ABL001 together with three other medicines (dasatinib, prednisone, and blinatumomab) in people with BCR-ABL positive B-cell acute lymphoblastic leukemia or chronic myeloid leukemia in blast crisis. The study aims to find the saf…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Marlise Luskin, MD • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for tough blood cancers? early trial launches
Disease control Recruiting nowThis early-stage study is testing a new biologic drug called CC312 in 44 adults with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to standard treatments. The main goals are to check safety and find the right dose. Participants receive CC31…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Engineered immune cells take on tough leukemia in kids
Disease control Recruiting nowThis early-stage trial is testing a type of immunotherapy called CAR T cells in children, adolescents, and young adults with acute lymphoblastic leukemia that has come back or not responded to standard treatments. The therapy involves taking the patient's own immune cells or dono…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Instituto de Investigación Hospital Universitario La Paz • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New cell therapy GT719 targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing an experimental cell therapy called GT719 in 46 adults with relapsed or treatment-resistant B-cell lymphoma or leukemia that tests positive for CD19. The study aims to see if the treatment is safe and how well it works. Participants receive a sin…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 26, 2026 18:26 UTC
-
Engineered immune cells take on tough leukemia
Disease control Recruiting nowThis study is testing a new treatment called UCART22 for people with a type of blood cancer called B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. UCART22 uses donor immune cells that are engineered in a lab to recognize and attack …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Cellectis S.A. • Aim: Disease control
Last updated Jun 26, 2026 14:53 UTC
-
Smart testing after CAR t: could it spare kids from unneeded transplants?
Knowledge-focused Recruiting nowThis study tests whether regular blood and bone marrow tests using advanced DNA sequencing can better monitor children with B-cell acute lymphoblastic leukemia (B-ALL) after they achieve remission with CAR T therapy. The goal is to see if these tests can identify who is truly cur…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 02:00 UTC
-
New registry to reveal how blinatumomab works in everyday leukemia care
Knowledge-focused Recruiting nowThis study is a registry that collects data from 200 adults with B-cell acute lymphoblastic leukemia who received blinatumomab as part of their treatment outside of a clinical trial. Researchers will look at how many patients achieve complete remission and overall survival. The g…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New screening trial aims to match kids with relapsed leukemia to targeted therapies
Knowledge-focused Recruiting nowThis study screens children and young adults up to age 22 whose leukemia has returned or is hard to treat. By testing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to build a r…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: PedAL BCU, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks hidden dangers of CAR t therapy in kids
Knowledge-focused Recruiting nowThis study follows 100 children and young adults who received CAR T cell therapy to understand short- and long-term side effects like infections, slow blood cell recovery, and nerve problems. Researchers will check participants at 3, 6, 12, and 24 months after treatment. The goal…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
500 patients to be tracked for long-term safety of cancer cell therapy
Knowledge-focused Recruiting nowThis study follows 500 people in South Korea who have received tisagenlecleucel, a CAR-T cell therapy, for certain blood cancers like acute lymphoblastic leukemia and lymphomas. Researchers will monitor side effects, risk of new cancers, and how well the treatment works over time…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study maps Kids' leukemia to match best treatment
Knowledge-focused Recruiting nowThis study enrolls children and teens (ages 1-18) newly diagnosed with certain types of leukemia or lymphoma. The main goal is to gather enough information from their tumor samples to figure out their risk of the cancer coming back, so they can be placed into the right treatment …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE4 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Leukemia treatment may erase vaccine protection—study tests if re-vaccination works
Knowledge-focused Recruiting nowThis study looks at whether children and young adults (up to age 21) treated for B-cell acute lymphoblastic leukemia with the immunotherapy drug blinatumomab still have protection from routine childhood vaccines. Researchers will measure antibody levels for diseases like tetanus,…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Arkansas Children's Hospital Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC